Adicet Bio 10-Q 9 Nov 18 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Sep. 30, 2018	Nov. 05, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ACETO CORP
Entity Central Index Key	2,034
Trading Symbol	acet
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Entity Common Stock Shares Outstanding		30,765,639
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q1
Entity Small Business	false
Entity Emerging Growth Company	false

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Current assets:
Cash and cash equivalents	$ 51,547	$ 100,874
Investments	955	3,030
Trade receivables, less allowance for doubtful accounts (September 30, 2018, $979; June 30, 2018, $987)	292,378	247,246
Other receivables	8,810	9,664
Inventory	156,527	137,076
Prepaid expenses and other current assets	6,383	4,737
Total current assets	516,600	502,627
Property and equipment, net	13,689	14,180
Property held for sale	6,113	6,113
Goodwill	1,876	1,883
Intangible assets, net	227,738	234,602
Other assets	8,619	7,619
TOTAL ASSETS	774,635	767,024
Current liabilities:
Current portion of long-term debt	14,482	14,482
Accounts payable	123,384	106,790
Accrued expenses	196,086	181,246
Total current liabilities	333,952	302,518
Long-term debt, net	300,900	302,916
Long-term liabilities	64,295	64,558
Environmental remediation liability		211
Deferred income tax liability	1,726	1,536
Total liabilities	700,873	671,739
Commitments and contingencies (Note 7)
Shareholders' equity:
Preferred stock, 2,000 shares authorized; no shares issued and outstanding
Common stock, $.01 par value, 75,000 shares authorized; 30,801 and 30,787 shares issued and outstanding at September 30, 2018 and June 30, 2018, respectively	308	308
Capital in excess of par value	222,578	222,599
Accumulated deficit	(148,117)	(126,737)
Accumulated other comprehensive loss	(1,007)	(885)
Total shareholders' equity	73,762	95,285
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 774,635	$ 767,024

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts (in dollars)	$ 979	$ 987
Preferred stock, shares authorized	2,000	2,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	75,000	75,000
Common stock, shares issued	30,801	30,787
Common stock, shares outstanding	30,801	30,787

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net sales	$ 164,405	$ 185,255
Cost of sales	138,925	145,272
Gross profit	25,480	39,983
Selling, general and administrative expenses	36,897	31,149
Research and development expenses	1,881	1,615
Operating (loss) income	(13,298)	7,219
Other (expense) income:
Interest expense	(6,138)	(5,355)
Interest and other income, net	341	274
Other (expense) income, Total	(5,797)	(5,081)
(Loss) income before income taxes	(19,095)	2,138
Income tax provision	1,997	1,684
Net (loss) income	$ (21,092)	$ 454
Basic (loss) income per common share (in dollars per share)	$ (0.59)	$ 0.01
Diluted (loss) income per common share (in dollars per share)	$ (0.59)	$ 0.01
Weighted average shares outstanding:
Basic (in shares)	35,487	34,975
Diluted (in shares)	35,487	35,259

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Statement of Comprehensive (loss) Income [Abstract]
Net (loss) income	$ (21,092)	$ 454
Other comprehensive (loss) income:
Foreign currency translation adjustments	(334)	2,320
Change in fair value of interest rate swaps	212	106
Comprehensive (loss) income	$ (21,214)	$ 2,880

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating activities:
Net (loss) income	$ (21,092)	$ 454
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Depreciation and amortization	8,043	8,301
Amortization of debt issuance costs and debt discount	1,600	1,513
Amortization of deferred financing costs	282	270
Provision for doubtful accounts	(7)	(15)
Non-cash stock compensation	(24)	3,146
Deferred income taxes	146	(1,099)
Environmental charge		902
Earnings on equity investment in joint venture	(708)	(231)
Changes in assets and liabilities:
Trade accounts receivable	(45,332)	21,137
Other receivables	582	149
Inventory	(19,639)	2,225
Prepaid expenses and other current assets	(1,657)	(944)
Other assets	(481)	(334)
Accounts payable	16,691	7,699
Accrued expenses and other liabilities	15,161	792
Net cash (used in) provided by operating activities	(46,435)	43,965
Investing activities:
Purchases of investments	(653)	(2,655)
Sales of investments	2,673	1,646
Payments for intangible assets	(520)	(54)
Purchases of property and equipment, net	(185)	(1,506)
Net cash provided by (used in) investing activities	1,315	(2,569)
Financing activities:
Payment of cash dividends		(1,935)
Proceeds from exercise of stock options		73
Repayment of bank loans	(3,799)	(23,783)
Net cash used in financing activities	(3,799)	(25,645)
Effect of exchange rate changes on cash	(408)	669
Net (decrease) increase in cash	(49,327)	16,420
Cash and cash equivalents at beginning of period	100,874	55,680
Cash and cash equivalents at end of period	51,547	$ 72,100
Non-Cash Item
Dividends declared but not paid	$ 306

Basis of Presentation

Basis of Presentation	3 Months Ended
	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	(1) Basis of Presentation The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation. These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2018.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Revenue Recognition	(2) Revenue Recognition The Company adopted ASU 2014-09, Revenue from Contracts with Customers (Topic 606) All revenue recognized in the accompanying unaudited interim condensed consolidated financial statements of operations is considered to be revenue from contracts with customers. The Company recognizes revenue from product sales at the time of shipment and upon the transfer of control of the Company’s product. The Company has no acceptance or other post-shipment obligations and does not offer product warranties or services to its customers. The Company generally does not have incremental costs to obtain contracts that would otherwise not have been incurred. Payment terms can vary by the type and location of the customer. The term between invoicing and when payment is due is typically 30 to 90 days. The following tables show the Company’s revenues disaggregated by business segment and product lines offered to customers: Three months ended September 30, 2018 Human Health Pharmaceutical Performance Consolidated Finished dosage form generic drugs $ 69,213 - - $ 69,213 Nutraceutical products 11,633 - - 11,633 Pharmaceutical intermediates - $ 10,222 - 10,222 Active pharmaceutical ingredients (APIs) - 28,626 - 28,626 Specialty chemicals - - $ 36,221 36,221 Agricultural protection products - - 8,490 8,490 $ 80,846 $ 38,848 $ 44,711 $ 164,405 Three months ended September 30, 2017 Human Health Pharmaceutical Performance Consolidated Finished dosage form generic drugs $ 95,561 - - $ 95,561 Nutraceutical products 10,454 - - 10,454 Pharmaceutical intermediates - $ 10,136 - 10,136 Active pharmaceutical ingredients (API's) - 26,440 - 26,440 Specialty chemicals - - $ 34,020 34,020 Agricultural protection products - - 8,644 8,644 $ 106,015 $ 36,576 $ 42,664 $ 185,255 Variable Consideration The Company has arrangements with various third parties, such as drug store chains and managed care organizations, establishing prices for its finished dosage form generics. While these arrangements are made between Aceto and its customers, the customers independently select a wholesaler from which they purchase the products. Alternatively, certain wholesalers may enter into agreements with the customers, with the Company’s concurrence, which establishes the pricing for certain products which the wholesalers provide. Upon each sale of finished dosage form generics, significant estimates of chargebacks, rebates, returns, government reimbursed rebates, sales discounts and other adjustments are made. These estimates are accounted for as variable consideration and are recorded as reductions to gross revenues, with corresponding adjustments either as a reduction of accounts receivable or as a liability for price concessions. The Company estimates variable consideration after considering applicable information that is reasonably available. These estimates are based on historical experience, future expectations, contractual arrangements with wholesalers and indirect customers, and other factors known to management at the time of accrual. The consideration the Company receives in exchange for its goods is only recognized when it is probable that a significant reversal will not occur. Chargebacks Under certain arrangements, Rising will issue a credit (referred to as a “chargeback”) to the wholesaler for the difference between the invoice price to the wholesaler and the customer’s contract price. In order to calculate the chargeback allowance, prior period chargebacks claimed by wholesalers are analyzed to determine the average chargeback amount for each product and wholesaler. These amounts are adjusted for any information that will better reflect future average chargeback amounts. Management receives on-hand inventory reports from wholesalers to which the average chargeback amount is applied. The provision for chargebacks varies in relation to changes in sales volume, product and customer mix, terms with customers, pricing, changes in Wholesale Acquisition Cost (“WAC”), the level of inventory at the wholesalers, and changes in the volume of off-contract purchases. As sales to the large wholesale customers increase or decrease, the reserve for chargebacks will also generally increase or decrease. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks may differ from the actual chargeback reserve. Returns The Company maintains a policy that allows customers to return product within a specified period prior to and subsequent to the product expiration date. Product returns are settled through a credit issued to the customer. The Company estimates its provision for returns of finished dosage generics based on historical experience, product expiration dates, changes to business practices, credit terms, new competition, shortages in the market and any extenuating circumstances known to management. While historical experience has allowed for reasonable estimations in the past, future returns may or may not follow historical trends. Generally, the reserve for returns increases as net sales increase. The Company continually monitors the reserve for returns and makes adjustments when management believes that actual product returns may differ from the established reserve. Sales of nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, including agricultural intermediates and agricultural protection products are recorded net of estimated returns of damaged goods from customers, which historically have been immaterial. Government Rebates Government rebates relate to our reimbursement arrangements with state and federal government agencies. Government rebate accruals are based on estimated payments due to governmental agencies for purchases made by plan participants. The Company provides a provision for government reimbursed rebates at the time of sale based on historical redemption rates. Government rebate amounts per product unit for generic products are established by law, based on the Average Manufacturer Price (“AMP”), which is reported on a monthly and quarterly basis. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly. Non-Governmental Rebates & Other Other rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. These rebates and other promotional programs vary by product and by volume purchase by each eligible customer. The Company provides a provision for other rebates at the time of sale based on contracted rates, actual product sales data and historical redemption rates. Aceto regularly reviews the information related to these estimates and adjusts the provision accordingly. Sales of nutraceutical products, pharmaceutical active ingredients and intermediates, specialty performance chemicals, including agricultural intermediates and agricultural protection products are recorded net of sales incentives which include volume incentive rebates. The Company records volume incentive rebates based on the underlying revenue transactions that result in progress by the customer in earning the rebate. Sales Discounts Sales discount accruals are based on payment terms extended to customers purchasing our finished dosage form generic products. The sales discount reserve is based on the invoices outstanding at period end and the sales discount rate. The following table summarizes activity in the consolidated balance sheet for contra assets and liability for price concessions for the quarter ended September 30, 2018: Accruals for Chargebacks, Rebates, Returns and Other Allowances Government Non-Governmental Sales Chargebacks Returns Reimbursed Rebates Rebates & Other Discounts Balance at June 30, 2018 $ 66,687 $ 41,511 $ 9,658 $ 86,259 $ 6,408 Current period provision 184,559 6,465 3,061 43,386 6,584 Credits issued during the period (157,732 ) (2,220 ) (3,357 ) (30,717 ) (1,991 ) Balance at September 30, 2018 $ 93,514 $ 45,756 $ 9,362 $ 98,928 $ 11,001 Credits issued during a given period represent cash payments or credit memos issued to the Company’s customers as settlement for the related reserve. Management has the experience and access to relevant information that it believes is necessary to reasonably estimate the amounts of such deductions from gross revenues. The Company regularly reviews the information related to these estimates and adjusts its reserves accordingly, if and when actual experience differs from previous estimates. The Company has not experienced any significant changes in its estimates as it relates to its chargebacks, rebates, sales discounts or product returns for the periods presented.

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Sep. 30, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	(3) Stock-Based Compensation Under the Aceto Corporation 2015 Equity Participation Plan (the “2015 Plan”), grants of stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards (“Stock Awards”) may be offered to employees, non-employee directors, consultants and advisors of the Company, including the chief executive officer, chief financial officer and other named executive officers. The maximum number of shares of common stock of the Company that may be issued pursuant to Stock Awards granted under the 2015 Plan will not exceed, in the aggregate, 4,250 shares. Stock Awards that are intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, may be granted. Performance-based awards may be granted, vested and paid based on the attainment of specified performance goals. Under the Aceto Corporation 2010 Equity Participation Plan (as amended and restated in 2012, the “2010 Plan”), grants of stock options, restricted stock, restricted stock units, stock appreciation rights, and stock bonuses may be made to employees, non-employee directors and consultants of the Company. The maximum number of shares of common stock of the Company that may be issued pursuant to awards granted under the 2010 Plan will not exceed, in the aggregate, 5,250 shares. In addition, restricted stock may be granted to an eligible participant in lieu of a portion of any annual cash bonus earned by such participant. Such award may include additional shares of restricted stock (premium shares) greater than the portion of bonus paid in restricted stock. The restricted stock award is vested at issuance and the restrictions lapse ratably over a period of years as determined by the Board of Directors, generally three years. The premium shares vest when all the restrictions lapse, provided that the participant remains employed by the Company at that time. During the three months ended September 30, 2018, there were no grants of restricted common stock. During the three months ended September 30, 2017, the Company granted 337 shares of restricted common stock to its employees that vest over three years. In addition, during the three months ended September 30, 2017, the Company also issued a target grant of 168 performance-vested restricted stock units, which grant could be as much as 294 units if certain performance criteria and market conditions are met. These performance-vested restricted stock units will cliff vest 100% at the end of the third year following grant in accordance with the performance metrics set forth in the applicable employee performance-vested restricted stock unit grant. For the three months ended September 30, 2018 and 2017, the Company recorded stock-based compensation (benefit) expense of approximately $(24), which includes forfeitures, and $3,132, respectively, related to restricted common stock and restricted stock units. Included in the stock-based compensation expense for the three months ended September 30, 2017 is $2,017 associated with the separation of the Company’s former Chief Executive Officer in September 2017. As of September 30, 2018, the total unrecognized stock-based compensation cost is approximately $4,476.

Capital Stock

Capital Stock	3 Months Ended
	Sep. 30, 2018
Equity [Abstract]
Capital Stock	(4) Capital Stock On September 6, 2018, the Company's board of directors declared a regular quarterly dividend of $.01 per share which was distributed on October 9, 2018 to shareholders of record as of September 24, 2018. On May 4, 2017, the Board of Directors of the Company authorized the continuation of the Company’s stock repurchase program, expiring in May 2020. Under the stock repurchase program, the Company is authorized to purchase up to 5,000 shares of common stock in open market or private transactions, at prices not to exceed the market value of the common stock at the time of such purchase. The Company did not repurchase shares in the three months ended September 30, 2018 or in fiscal year 2018. The Company is authorized to issue 75,000 shares of Common Stock and 2,000 shares of Preferred Stock. The Board of Directors has authority under the Company’s Restated Certificate of Incorporation to issue shares of preferred stock with voting and other relative rights to be determined by the Board of Directors.

Net Income Per Common Share

Net Income Per Common Share	3 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Net Income Per Common Share	(5) Net Income Per Common Share Basic income per common share is based on the weighted average number of common shares outstanding during the period. Diluted income per common share includes the dilutive effect of potential common shares outstanding. The following table sets forth the reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding: Three Months Ended September 30, 2018 2017 Weighted average shares outstanding 35,487 34,975 Dilutive effect of stock options and restricted stock awards and units - 284 Diluted weighted average shares outstanding 35,487 35,259 The effect of approximately 35 common equivalent shares for the three months ended September 30, 2018 was excluded from the diluted weighted average shares outstanding due to a net loss for the period. There were 1,171 common equivalent shares outstanding for the three months ended September 30, 2018 that were not included in the calculation of diluted net income per common share because their effect would have been anti-dilutive. The weighted average shares outstanding for the three months ended September 30, 2018 and 2017 includes the effect of 5,122 shares to be issued in connection with the acquisition of certain products and related assets from Citron and Lucid. The Convertible Senior Notes (see Note 6) will only be included in the dilutive net income per share calculations using the treasury stock method during periods in which the average market price of Aceto’s common stock is above the applicable conversion price of the Convertible Senior Notes, or $33.215 per share, and the impact would not be anti-dilutive. There were 61 common equivalent shares outstanding as of September 30, 2017 that were not included in the calculation of diluted net income per common share for the three months ended September 30, 2017 because their effect would have been anti-dilutive.

Debt

Debt	3 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Debt	(6) Debt Long-term debt September 30, 2018 June 30, 2018 Convertible Senior Notes, net $ 129,457 $ 127,857 Revolving Bank Loans 62,000 62,000 Term Bank Loans 121,392 124,959 Mortgage 2,533 2,582 315,382 317,398 Less current portion 14,482 14,482 $ 300,900 $ 302,916 Convertible Senior Notes In November 2015, Aceto offered $125,000 aggregate principal amount of Convertible Senior Notes due 2020 (the "Notes") in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. In addition, Aceto granted the initial purchasers for the offering an option to purchase up to an additional $18,750 aggregate principal amount pursuant to the initial purchasers’ option to purchase additional Notes, which was exercised in November 2015. Therefore, the total offering was $143,750 aggregate principal amount. The Notes are unsecured obligations of Aceto and rank senior in right of payment to any of Aceto’s subordinated indebtedness, equal in right of payment to all of Aceto’s unsecured indebtedness that is not subordinated, effectively junior in right of payment to any of Aceto’s secured indebtedness to the extent of the value of the assets securing such indebtedness and structurally junior in right of payment to all indebtedness and other liabilities (including trade payables) of Aceto’s subsidiaries. The Notes will be convertible into cash, shares of Aceto common stock or a combination thereof, at Aceto’s election, upon the satisfaction of specified conditions and during certain periods. The Notes will mature in November 2020. The Notes pay 2.0% interest semi-annually in arrears on May 1 and November 1 of each year, which commenced on May 1, 2016. The Notes are convertible into 4,328 shares of common stock, based on an initial conversion price of $33.215 per share. Holders may convert all or any portion of their notes, in multiples of one thousand dollar principal amount, at their option at any time prior to the close of business on the business day immediately preceding May 1, 2020 only under the following circumstances: (i) during any calendar quarter (and only during such calendar quarter), if the last reported sale price of the common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day, (ii) during the five consecutive business day period after any five consecutive trading day period (which is referred to as the “measurement period”) in which the trading price per one thousand dollar principal amount of Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of Aceto’s common stock and the conversion rate on each such trading day; or (iii) upon the occurrence of specified corporate events. Upon conversion by the holders, the Company may elect to settle such conversion in shares of its common stock, cash, or a combination thereof. As a result of its cash conversion option, the Company separately accounted for the value of the embedded conversion option as a debt discount (with an offset to capital in excess of par value). The debt discount is being amortized as additional non-cash interest expense using the effective interest method over the term of the Notes. Debt issuance costs are being amortized as additional non-cash interest expense. In connection with the offering of the Notes, Aceto entered into privately negotiated convertible note hedge transactions with option counterparties, which are affiliates of certain of the initial purchasers. The convertible note hedge transactions are expected generally to reduce the potential dilution to Aceto’s common stock and/or offset any cash payments Aceto is required to make in excess of the principal amount of converted Notes upon any conversion of Notes. Aceto also entered into privately negotiated warrant transactions with the option counterparties. The warrant transactions could separately have a dilutive effect to the extent that the market price per share of Aceto’s common stock as measured over the applicable valuation period at the maturity of the warrants exceeds the applicable strike price of the warrants. By entering into these transactions with the option counterparties, the Company issued convertible debt and a freestanding “call-spread.” The carrying value of the Notes is as follows: September 30, 2018 June 30, 2018 Principal amount $ 143,750 $ 143,750 Unamortized debt discount (12,518 ) (13,909 ) Unamortized debt issuance costs (1,775 ) (1,984 ) Net carrying value $ 129,457 $ 127,857 The following table sets forth the components of total “interest expense” related to the Notes recognized in the accompanying condensed consolidated statements of operations for the three months ended September 30: 2018 2017 Contractual coupon $ 670 $ 709 Amortization of debt discount 1,391 1,304 Amortization of debt issuance costs 209 209 $ 2,270 $ 2,222 Credit Facilities On December 21, 2016 the Company entered into a Second Amended and Restated Credit Agreement (the “A&R Credit Agreement”), with eleven banks, which amended and restated in its entirety the Amended and Restated Credit Agreement, dated as of October 28, 2015, as amended by Amendment No. 1 to Amended and Restated Credit Agreement, dated as of November 10, 2015, and Amendment No. 2 to Amended and Restated Credit Agreement, dated as of August 26, 2016 (collectively, the “First Amended Credit Agreement”). The A&R Credit Agreement increased the aggregate available revolving commitment under the First Amended Credit Agreement from $150,000 to an initial aggregate available revolving commitment of $225,000 (the “Initial Revolving Commitment”). Under the A&R Credit Agreement, the Company was permitted to borrow, repay and reborrow from and as of December 21, 2016, to but excluding December 21, 2021 (the “Maturity Date”) provided, that if any of the Notes remain outstanding on the date that is 91 days prior to the maturity date of the Notes (the “2015 Convertible Maturity Date”), then the Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date. The A&R Credit Agreement provides for (i) Eurodollar Loans (as such terms are defined in the A&R Credit Agreement), (ii) ABR Loans (as such terms are defined in the A&R Credit Agreement), or (iii) a combination thereof. As of September 30, 2018, the Company borrowed Revolving Loans (as defined under the A&R Credit Agreement) aggregating $62,000 which loans are Eurodollar Loans at interest rates ranging from 5.00% to 5.02% at September 30, 2018. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio. Under the A&R Credit Agreement, the Company also borrowed $150,000 in term loans (the “Initial Term Loan). Subject to certain conditions, including obtaining commitments from existing or prospective lenders, the Company had the right to increase the amount of the Initial Revolving Commitment (each, a “Revolving Facility Increase” and, together with the Initial Revolving Commitment, the “Revolving Commitment”) and/or the Initial Term Loan in an aggregate amount not to exceed $100,000 pursuant to an incremental loan feature in the A&R Credit Agreement. As of September 30, 2018, the remaining amount outstanding under the Initial Term Loan was $123,750 and was payable as a Eurodollar Loan at an interest rate of 9.39%. The proceeds of the Initial Revolving Commitment and Initial Term Loan were used to partially finance the acquisition of generic products and related assets of Citron and its affiliate Lucid, and pay fees and expenses related thereto. The applicable interest rate margin percentage is subject to adjustment quarterly based upon the Company’s senior secured net leverage ratio. The Initial Term Loan is payable as to principal in nineteen consecutive, equal quarterly installments of $3,750, which commenced on March 31, 2017 and will continue on each March 31, June 30, September 30 and December 31 thereafter. To the extent not previously paid, the final payment on the Term Loan Maturity Date (as defined in the A&R Credit Agreement) shall be in an amount equal to the then outstanding unpaid principal amount of the Initial Term Loan. The A&R Credit Agreement provides that commercial letters of credit shall be issued to provide the primary payment mechanism in connection with the purchase of any materials, goods or services in the ordinary course of business. The Company had no open letters of credit at September 30, 2018 and June 30, 2018. In accordance with generally accepted accounting principles, deferred financing costs associated with the Initial Term Loan are presented as a direct deduction from the carrying value of the debt liability rather than showing the deferred financing costs as a deferred charge on the balance sheet. In addition, deferred financing costs associated with the Revolving Commitment have been recorded as a deferred charge on the balance sheet. The A&R Credit Agreement provides for a security interest in substantially all of the personal property of the Company and certain of its subsidiaries. The A&R Credit Agreement contains several financial covenants including, among other things, maintaining a minimum level of debt service and certain leverage ratios. Under the A&R Credit Agreement, the Company and its subsidiaries are also subject to certain restrictive covenants, including, among other things, covenants governing liens, limitations on indebtedness, limitations on guarantees, limitations on sales of assets and sales of receivables, and limitations on loans and investments. On December 13, 2017, the Company entered into a First Amendment to the Second Amended and Restated Credit Agreement (the “2017 Amendment”), which amended the A&R Credit Agreement. The 2017 Amendment, among other things, contained several amendments to the financial covenants in the A&R Credit Agreement. On May 3, 2018, the Company entered into a Second Amendment and Waiver to the Second Amended and Restated Credit Agreement (the “May 2018 Amendment”). The May 2018 Amendment, among other things, contained a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with Total Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarter ended March 31, 2018. The May 2018 Amendment also contained several amendments to the A&R Credit Agreement including, among other things, reducing the available revolving commitment thereunder to $100,000, fixing the applicable margin on loans to the highest level provided under the A&R Credit Agreement at the time, fixing the commitment fee on the undrawn revolving commitments to the highest level provided under the A&R Credit Agreement at the time, requiring prior written consent of Required Lenders (as defined in the A&R Credit Agreement) as a condition precedent to the lenders making any additional loans or extending any further credit, restricting dividends or distributions the Company may make to its shareholders to no more than $0.01 per share for the quarter ending on June 30, 2018 and restricting dividends or distributions thereafter, restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions As of June 30, 2018, the Company was not in compliance with its financial covenants relating to its Total Net Leverage Ratio, Senior Secured Net Leverage Ratio and Debt Service Coverage Ratio. The Company and its lenders agreed upon another amendment to the A&R Credit Agreement (referred to herein as the “September 2018 Amendment”). The September 2018 Amendment provides for a waiver of any event of default under the A&R Credit Agreement arising as a result of the non-compliance by the Company with the Total Net Leverage Ratio, Senior Secured Net Leverage Ratio and Debt Service Coverage Ratio financial covenants, in each case, solely for the fiscal quarters ended or ending June 30, 2018, September 30, 2018, December 31, 2018, March 31, 2019 and June 30, 2019. The September 2018 Amendment also contains several amendments to the A&R Credit Agreement including, among other things, (a) a limitation on dividends for the fiscal quarters ending September 30, 2018, December 31, 2018, March 31, 2019 and June 30, 2019, to an amount not to exceed $325 for any fiscal quarter, (b) increasing the applicable margin with respect to the interest rates on all loans under the A&R Credit Agreement by 450 basis points and fixing (during the September 2018 Amendment Limitation Period (as hereinafter defined)) the applicable margin with respect to the interest rate on all loans under the A&R Credit Agreement to the highest level provided under the A&R Credit Agreement which is currently 6.00% in the case of ABR Loans (as defined in the A&R Credit Agreement) and 7.00% in the case of Eurodollar Loans (as defined in the A&R Credit Agreement), (c) during the period commencing on the closing of the September 2018 Amendment and ending on the date the Company demonstrates compliance with each financial covenant set forth in the A&R Credit Agreement for the fiscal quarter ending September 30, 2019 (referred to herein as “the September 2018 Amendment Limitation Period”; provided that if the Company is not in compliance with any of the financial covenants set forth in the A&R Credit Agreement for the fiscal quarter ending September 30, 2019, then the September 2018 Amendment Limitation Period shall continue indefinitely), requiring the Company to maintain the sum of Domestic Liquidity (as defined in the A&R Credit Agreement) plus Foreign Liquidity (as defined in the A&R Credit Agreement) and the undrawn portion of the Revolving Commitment (as defined in the A&R Credit Agreement) (referred to herein as “Covenant Liquidity”) to an amount of at least $55,000 (the “Covenant Liquidity Amount”) as of the last business day of each week following the effectiveness of the September 2018 Amendment; provided that the Company shall not be in breach of the minimum liquidity covenant unless the Covenant Liquidity is less than the Covenant Liquidity Amount as of the last business day of two consecutive weeks, (d) requiring the prior written consent of the Required Lenders as a condition precedent to the lenders extending any Loans (as defined in the A&R Credit Agreement) or the issuing banks issuing, amending, renewing or extending any Letter of Credit, (e) permitting the purchase, during fiscal 2019, of assets for an aggregate consideration not to exceed $12,300, consisting of intangibles assets relating to strategic product acquisitions and certain capital expenditures, and (f) restricting the incurrence of certain indebtedness, limiting acquisitions and other investments and imposing certain other restrictions In conjunction with the Credit Agreement, the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge. The expiration date of this interest rate swap is December 21, 2021. The remaining notional balance of this derivative as of September 30, 2018 is $82,500. Mortgage On June 30, 2011, the Company entered into a mortgage payable for $3,947 on its corporate headquarters, in Port Washington, New York. This mortgage payable is secured by the land and building and is being amortized over a period of 20 years. The mortgage payable, which was modified in October 2013, bears interest at 4.92% per annum as of September 30, 2017 and matures on June 30, 2021.

Commitments, Contingencies and

Commitments, Contingencies and Other Matters	3 Months Ended
	Sep. 30, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments, Contingencies and Other Matters	(7) Commitments, Contingencies and Other Matters The Company and its subsidiaries are subject to various claims which have arisen in the normal course of business. The Company provides for costs related to contingencies when a loss from such claims is probable and the amount is reasonably determinable. In determining whether it is possible to provide an estimate of loss, or range of possible loss, the Company reviews and evaluates its litigation and regulatory matters on a quarterly basis in light of potentially relevant factual and legal developments. If the Company determines an unfavorable outcome is not probable or reasonably estimable, the Company does not accrue for a potential litigation loss. While the Company has determined that there is a reasonable possibility that a loss has been incurred, no amounts have been recognized in the financial statements, other than what has been discussed below, because the amount of the liability cannot be reasonably estimated at this time. In fiscal years 2011, 2009, 2008 and 2007, the Company received letters from the Pulvair Site Group, a group of potentially responsible parties (PRP Group) who are working with the State of Tennessee (the State) to remediate a contaminated property in Tennessee called the Pulvair site. The PRP Group has alleged that Aceto shipped hazardous substances to the site which were released into the environment. The State had begun administrative proceedings against the members of the PRP Group and Aceto with respect to the cleanup of the Pulvair site and the PRP Group has begun to undertake cleanup. The PRP Group is seeking a settlement of approximately $1,700 from the Company for its share to remediate the site contamination. Although the Company acknowledges that it shipped materials to the site for formulation over twenty years ago, the Company believes that the evidence does not show that the hazardous materials sent by Aceto to the site have significantly contributed to the contamination of the environment and thus believes that, at most, it is a de minimis contributor to the site contamination. Accordingly, the Company believes that the settlement offer is unreasonable. Management believes that the ultimate outcome of this matter will not have a material adverse effect on the Company's financial condition or liquidity. The Company has environmental remediation obligations in connection with Arsynco, Inc. (“Arsynco”), a subsidiary formerly involved in manufacturing chemicals located in Carlstadt, New Jersey, which was closed in 1993 and is currently held for sale. Based on continued monitoring of the contamination at the site and the approved plan of remediation, Arsynco received an estimate from an environmental consultant stating that the costs of remediation could be between $22,900 and $24,700. Remediation commenced in fiscal 2010, and as of September 30, 2018 and June 30, 2018, a liability of $4,943 and $5,746, respectively, is included in the accompanying consolidated balance sheets for this matter. For the three months ended September 30, 2017, the Company recorded an environmental charge of $902, which is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations. In accordance with GAAP, management believes that the majority of costs incurred to remediate the site will be capitalized in preparing the property which is currently classified as held for sale. In June 2018, the Company entered into an agreement to sell the Arsynco property to an unrelated third party for $6,340. The sale is subject to due diligence by the buyer and the Company is not sure when or if the sale will close. The sale price supports the assumption that the expected fair value after the remediation is in excess of the amount required to be capitalized. However, these matters, if resolved in a manner different from those assumed in current estimates, could have a material adverse effect on the Company’s financial condition, operating results and cash flows when resolved in a future reporting period. In connection with the environmental remediation obligation for Arsynco, in July 2009, Arsynco entered into a settlement agreement with BASF Corporation (“BASF”), the former owners of the Arsynco property. In accordance with the settlement agreement, BASF paid for a portion of the prior remediation costs and going forward, will co-remediate the property with the Company. The contract requires that BASF pay $550 related to past response costs and pay a proportionate share of the future remediation costs. Accordingly, the Company had recorded a gain of $550 in fiscal 2009. This $550 gain relates to the partial reimbursement of costs of approximately $1,200 that the Company had previously expensed. The Company also recorded an additional receivable from BASF, with an offset against property held for sale, representing its estimated portion of the future remediation costs. The balance of this receivable for future remediation costs as of September 30, 2018 and June 30, 2018 is $2,224 and $2,586, respectively, which is included in the accompanying consolidated balance sheets. In March 2006, Arsynco received notice from the EPA of its status as a PRP under the Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) for a site described as the Berry’s Creek Study Area (“BCSA”). Arsynco is one of over 150 PRPs which have potential liability for the required investigation and remediation of the site. The estimate of the potential liability is not quantifiable for a number of reasons, including the difficulty in determining the extent of contamination and the length of time remediation may require. In addition, any estimate of liability must also consider the number of other PRPs and their financial strength. In July 2014, Arsynco received notice from the U.S. Department of Interior (“USDOI”) regarding the USDOI’s intent to perform a Natural Resource Damage (NRD) Assessment at the BCSA. Arsynco has to date declined to participate in the development and performance of the NRD assessment process. Based on prior practice in similar situations, it is possible that the State may assert a claim for natural resource damages with respect to the Arsynco site itself, and either the federal government or the State (or both) may assert claims against Arsynco for natural resource damages in connection with Berry's Creek; any such claim with respect to Berry's Creek could also be asserted against the approximately 150 PRPs which the EPA has identified in connection with that site. Any claim for natural resource damages with respect to the Arsynco site itself may also be asserted against BASF, the former owners of the Arsynco property. In September 2012, Arsynco entered into an agreement with three of the other PRPs that had previously been impleaded into New Jersey Department of Environmental Protection, et al. v. Occidental Chemical Corporation, et al., Docket No. ESX-L-9868-05 (the "NJDEP Litigation") and were considering impleading Arsynco into the same proceeding. Arsynco entered into an agreement to avoid impleader. Pursuant to the agreement, Arsynco agreed to (1) a tolling period that would not be included when computing the running of any statute of limitations that might provide a defense to the NJDEP Litigation; (2) the waiver of certain issue preclusion defenses in the NJDEP Litigation; and (3) arbitration of certain potential future liability allocation claims if the other parties to the agreement are barred by a court of competent jurisdiction from proceeding against Arsynco. In July 2015, Arsynco was contacted by an allocation consultant retained by a group of the named PRPs, inviting Arsynco to participate in the allocation among the PRPs’ investigation and remediation costs relating to the BCSA. Arsynco declined that invitation. Since an amount of the liability cannot be reasonably estimated at this time, no accrual is recorded for these potential future costs. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known. A subsidiary of the Company markets certain agricultural protection products which are subject to the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA). FIFRA requires that test data be provided to the EPA to register, obtain and maintain approved labels for pesticide products. The EPA requires that follow-on registrants of these products compensate the initial registrant for the cost of producing the necessary test data on a basis prescribed in the FIFRA regulations. Follow-on registrants do not themselves generate or contract for the data. However, when FIFRA requirements mandate that new test data be generated to enable all registrants to continue marketing a pesticide product, often both the initial and follow-on registrants establish a task force to jointly undertake the testing effort. The Company is presently a member of several such task force groups, which requires payments for such memberships. In addition, in connection with our agricultural protection business, the Company plans to acquire product registrations and related data filed with the United States Environmental Protection Agency to support such registrations and other supporting data for several products. The acquisition of these product registrations and related data filed with the United States Environmental Protection Agency as well as payments to various task force groups could approximate $5,616 in fiscal 2019. In connection with the acquisition of certain products and related assets from Citron and Lucid, Aceto committed to make a $50,000 unsecured deferred payment that bears interest at a rate of 5% per annum to the sellers on December 21, 2021 and to issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The product purchase agreement also provides for a 5-year potential earn-out of up to an additional $50,000 in cash, based on the financial performance of four pre-specified pipeline products that are currently in development. As of September 30, 2018, the Company accrued $703 related to this contingent consideration. In February 2018, the Company was notified by the U.S. government that 11 generic drug products it acquired through its Acetris Health subsidiary in a product purchase agreement with Lucid were not in compliance with the federal Trade Agreement Act (“TAA”) country-of-origin provisions of a clause (the “Trade Agreements Clause”) contained in the government supply contracts acquired from Lucid (the “TAA Notification”). The 11 finished dosage form products purchased by the U.S. government are manufactured by Aurolife Pharma LLC which is located in Dayton, New Jersey using APIs sourced from India. In conjunction with this finding, the U.S. Department of Veterans Affairs (“VA”) requested that Acetris supply new TAA-compliant sources for the referenced products by March 9, 2018 and supply new TAA-compliant drugs to the government purchasers under the contracts by March 26, 2018. Acetris knew that it would be unable to meet these short deadlines. To avoid the government’s imposition of penalties for failure to meet these deadlines while Acetris appealed the above-mentioned findings, Acetris requested that the government defer imposition of these deadlines pending resolution of Acetris’ appeal. The Government declined this request and thereafter Acetris and the government entered into agreements that provided for a no-cost termination of each of the 11 supply contracts. On July 10, 2018, the Company was informed that Acetris received a favorable ruling from the United States Court of Federal Claims (the “Court”), in Acetris Health, LLC v. United States, invalidating the VA interpretation of the Trade Agreements Clause, which had resulted in the termination of 11 Acetris contracts with the VA. Finding in favor of Acetris, the Court granted a declaratory judgment establishing that under the federal Buy America Act the agencies are permitted to buy domestic end products, including commercial off-the-shelf products like generic drugs, that are manufactured in the United States when the Trade Agreements Clause is incorporated in government supply contracts, even if their components are not all manufactured in the United States. Although Department of Defense (the “DoD”) contracts were not at issue in the case, the decision also impacts Acetris’ ability to supply DoD with its products. The government’s appeal of the ruling is pending. Even if the Court’s ruling is affirmed on appeal, the Court’s ruling did not have the effect of reinstating the 11 terminated government supply agreements. Acetris may seek new contracts with these agencies, but no assurance can be given that any such contracts will be awarded. In March 2018, Sigmapharm Laboratories, LLC (“SigmaPharm”) commenced an action against Rising and the Company in the United States District Court for the Eastern District of Pennsylvania. The complaint arises out of an agreement, effective as of June 22, 2006 (the “SigmaPharm Agreement”), pursuant to which SigmaPharm agreed to supply certain generic pharmaceutical products (the “Products”) to Rising, and Rising in turn agreed to market and distribute the Products in the United States and pay SigmaPharm a share of the profits pursuant to a formula specified in the Agreement. The complaint alleges that Rising and Aceto breached the Agreement by failing to pay or timely make payments due under the Agreement and to disclose certain information to SigmaPharm. The complaint seeks, among other relief, a declaration that the Agreement has been terminated and that SigmaPharm has exclusive marketing and distribution rights to the Products; injunctive relief; and an unspecified amount of damages. In May 2018, Rising and the Company filed a motion to stay the action and compel arbitration, as required by the Agreement. In addition, SigmaPharm filed a “motion to enforce audit rights” in the federal litigation. On October 26, 2018, the district court granted Rising’s and the Company’s Motion to Stay and Compel Arbitration and denied Sigmapharm’s Motion to Enforce and Audit; thus the federal court action has been placed in suspense and the parties must proceed to arbitration. SigmaPharm has stopped supplying Products to Rising, claiming that it has validly terminated the Sigmapharm Agreement. Accordingly, in June 2018, Rising filed an arbitration claim against SigmaPharm in New Jersey, seeking recovery from SigmaPharm of any failure-to-supply losses Rising may incur as well as lost future profits on sale of the Products, among other relief. The Company intends to vigorously protect its rights in these matters and prosecute its claim for damages against SigmaPharm. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known. On April 16, 2018, the Company’s Rising subsidiary received a Grand Jury subpoena (the “DOJ Subpoena”) from the Antitrust Division of the DOJ. Rising is cooperating with the DOJ in response to the DOJ Subpoena. The Company and certain of its current and former officers are named defendants in two putative securities class actions (the “Securities Class Action Lawsuits”) filed in the United States District Court for the Eastern District of New York in April 2018, captioned Mulligan v. Aceto Corporation, et al, No. 2:18-cv-02425, and Yang v. Aceto Corporation, No. 1:18-cv-02437. The complaints arise from the April 19, 2018 drop in the Company’s stock price following the Company’s announcement on April 18, 2018 that it would recognize a substantial impairment charge for the third fiscal quarter. The complaints generally allege that the defendants violated the Securities Exchange Act of 1934 by making false and misleading statements in public filings with the SEC and seek unspecified damages. On June 26, 2018, five motions were filed seeking to appoint lead plaintiff and approve lead plaintiff’s counsel pursuant to the Private Securities Litigation Reform Act of 1995, as well as to consolidate the Mulligan or Yang actions. Three motions were subsequently withdrawn or abandoned, and the remaining two motions are pending before the Court. Following the appointment of a lead plaintiff, the Company expects that the appointed lead plaintiff will file a single consolidated amended class action complaint to supersede the earlier complaints. The Company intends to vigorously defend itself. The impact of the resolution of this matter on the Company’s results of operations in a particular reporting period is not currently known.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	(8) Fair Value Measurements GAAP defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly fashion between market participants at the measurement date. GAAP establishes a fair value hierarchy for those instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s assumptions (unobservable inputs). The hierarchy consists of three levels: Level 1 – Quoted market prices in active markets for identical assets or liabilities; Level 2 – Inputs other than Level 1 inputs that are either directly or indirectly observable; and Level 3 – Unobservable inputs that are not corroborated by market data. On a recurring basis, Aceto measures at fair value certain financial assets and liabilities, which consist of cash equivalents, investments and foreign currency contracts. The Company classifies cash equivalents and investments within Level 1 if quoted prices are available in active markets. Level 1 assets include instruments valued based on quoted market prices in active markets which generally include corporate equity securities publicly traded on major exchanges. Time deposits are very short-term in nature and are accordingly valued at cost plus accrued interest, which approximates fair value, and are classified within Level 2 of the valuation hierarchy. The Company uses foreign currency futures contracts to minimize the risk caused by foreign currency fluctuation on its foreign currency receivables and payables by purchasing futures with one of its financial institutions. Futures are traded on regulated U.S. and international exchanges and represent commitments to purchase or sell a particular foreign currency at a future date and at a specific price. Aceto’s foreign currency derivative contracts are classified within Level 2 as the fair value of these hedges is primarily based on observable futures foreign exchange rates. At September 30, 2018, the Company had foreign currency contracts outstanding that had a notional amount of $67,797. Unrealized (losses) gains on hedging activities for the three months ended September 30, 2018 and 2017, was $(331) and $295 respectively, and are included in interest and other income, net, in the consolidated statements of operations. The contracts have varying maturities of less than one year. In conjunction with its existing credit agreement (see Note 6), the Company entered into an interest rate swap on March 21, 2017 for an additional interest cost of 2.005% on a notional amount of $100,000, which has been designated as a cash flow hedge The expiration date of this interest rate swap is December 21, 2021. The remaining balance of this derivative as of September 30, 2018 is $82,500. The unrealized gain to date associated with this derivative, which is recorded in accumulated other comprehensive loss in the consolidated balance sheet at September 30, 2018, is $2,051. Aceto’s interest rate swaps are classified within Level 2 as the fair value of this hedge is primarily based on observable interest rates. At September 30, 2018 and June 30, 2018, the Company had $703 and $683, respectively, of contingent consideration which related to the acquisition of certain products and related assets of Citron and Lucid, which was completed in December 2016. The contingent consideration was calculated using the present value of a probability weighted income approach. The Company evaluates goodwill for impairment at the reporting unit level using a market participant approach using Level 3 inputs. Additionally, on a nonrecurring basis, the Company uses fair value measures when analyzing asset impairment. During the three months ended September 30, 2018 and 2017, there were no indicators of impairment. During the fiscal year ended June 30, 2018, the Company recognized a pre-tax non-cash goodwill impairment charge of $235,110 related to the Rising reporting unit. Long-lived assets and certain identifiable intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If it is determined such indicators are present and the review indicates that the assets will not be fully recoverable, based on undiscounted estimated cash flows over the remaining amortization periods, their carrying values are reduced to estimated fair value. Measurements based on undiscounted cash flows are Level 3 inputs. During the three months ended September 30, 2018 and 2017, there were no indicators of impairment. In connection with the acquisition of certain products and related assets of Citron and Lucid, the Company will issue 5,122 shares of Aceto common stock beginning on December 21, 2019. The fair value of the future issuance of these shares was determined to be $90,400 at the time of the product acquisition after taking into effect that the shares won’t be issued until the third and fourth anniversary of the closing and the present value calculation of dividends. In November 2015, the Company issued $143,750 aggregate principal amount of Notes (see Note 6). Since Aceto has the option to settle the potential conversion of the Notes in cash, the Company separated the embedded conversion option feature from the debt feature and accounts for each component separately, based on the fair value of the debt component assuming no conversion option. The calculation of the fair value of the debt component required the use of Level 3 inputs and was determined by calculating the fair value of similar non-convertible debt, using a theoretical borrowing rate of 6.5%. The value of the embedded conversion option was determined using an expected present value technique (income approach) to estimate the fair value of similar non-convertible debt onvertible investors’ credit assumptions and high yield bond indices. The Notes approximate a full fair value of $109,000 at September 30, 2018 giving effect to certain factors, including the term of the Notes, current stock price of Aceto stock and effective interest rate. The carrying values of all financial instruments classified as a current asset or current liability are deemed to approximate fair value because of the short maturity of these instruments. The fair values of the Company’s notes receivable and short-term and long-term bank loans were based upon current rates offered for similar financial instruments to the Company. The following tables summarize the valuation of the Company’s financial assets and liabilities which were determined by using the following inputs at September 30, 2018 and June 30, 2018: Fair Value Measurements at September 30, 2018 Using Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Total Cash equivalents: Time deposits - $ 3,092 - $ 3,092 Investments: Time deposits - 955 - 955 Foreign currency contracts-assets (1) - 55 - 55 Foreign currency contracts-liabilities (2) - 386 - 386 Derivative asset for interest rate swap (3) - 2,051 - 2,051 Contingent consideration (4) - - $ 703 703 (1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (3) Included in “Other Assets” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (4) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. Fair Value Measurements at June 30, 2018 Using Quoted Prices Significant (Level 2) Significant Unobservable (Level 3) Total Cash equivalents: Time deposits - $ 3,218 - $ 3,218 Investments: Time deposits - 3,030 - 3,030 Foreign currency contracts-assets (5) - 362 - 362 Foreign currency contracts-liabilities (6) - 304 - 304 Derivative asset for interest rate swap (7) - 1,839 - 1,839 Contingent consideration (8) - - $ 683 683 (5) Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (6) Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (7) Included in “Other Assets” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (8) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2018.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	3 Months Ended
	Sep. 30, 2018
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Recent Accounting Pronouncements	(9) Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Codification Improvements to Topic 842, Leases Leases (Topic 842), Targeted Improvements

Segment Information

Segment Information	3 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Segment Information	(10) Segment Information The Company's business is organized along product lines into three principal segments: Human Health, Pharmaceutical Ingredients and Performance Chemicals. Human Health Pharmaceutical Ingredients – Performance Chemicals Agricultural Protection Products include herbicides, fungicides and insecticides that control weed growth as well as control the spread of insects and other microorganisms that can severely damage plant growth. The Company's chief operating decision maker evaluates performance of the segments based on net sales, gross profit and income before income taxes. Unallocated corporate amounts are deemed by the Company as administrative, oversight costs, not managed by the segment managers. The Company does not allocate assets by segment because the chief operating decision maker does not review the assets by segment to assess the segments' performance, as the assets are managed on an entity-wide basis. During all periods presented, our chief operating decision maker has been the Chief Executive Officer of the Company. In accordance with GAAP, the Company has aggregated certain operating segments into reportable segments because they have similar economic characteristics, and the operating segments are similar in all of the following areas: (a) the nature of the products and services; (b) the nature of the production processes; (c) the type or class of customer for their products and services; (d) the methods used to distribute their products or provide their services; and (e) the nature of the regulatory environment. Three months Ended September 30, 2018 and 2017: Human Pharmaceutical Performance Chemicals Unallocated Consolidated 2018 Net sales $ 80,846 $ 38,848 $ 44,711 $ - $ 164,405 Gross profit 8,476 6,894 10,110 - 25,480 (Loss) income before income taxes (13,047 ) 3,398 5,928 (15,374 ) (19,095 ) 2017 Net sales $ 106,015 $ 36,576 $ 42,664 $ - $ 185,255 Gross profit 24,647 5,840 9,496 - 39,983 Income (loss) before income taxes 5,026 2,231 4,945 (10,064 ) 2,138

Subsequent Event

Subsequent Event	3 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Event	(11) Subsequent Event (to be updated by Lowenstein) On November 2, 2018, the Board approved the adoption of a Tax Asset Protection Plan and on November 5, 2018, the Company entered into a Tax Asset Protection Rights Agreement (the “Rights Agreement”), between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”). The purpose of the Rights Agreement is to help preserve the Company’s ability to utilize its significant tax benefits. On November 5, 2018, in connection with the entry into the Rights Agreement, the Board authorized and declared a dividend of one preferred stock purchase right (a “Right”) for each share of Common Stock outstanding as of the close of business on November 15, 2018 (the “Record Date”). Each Right entitles the registered holder to purchase from the Company one one-thousandth (subject to adjustment) of a share of Series A Participating Cumulative Preferred Stock, par value $2.50 per share (each, a “Series A Preferred Share” and collectively, the “Series A Preferred Shares”), of the Company at a price of $10.85 (as the same may be adjusted, the “Purchase Price”), and upon the terms and conditions set forth in the Rights Agreement. The Rights become exercisable upon (i) a shareholder acquiring beneficial ownership of 4.99% or more of the outstanding shares of the Company’s common stock without prior approval of the Board, or (ii) a shareholder who already beneficially owns 4.99% or more of the outstanding shares of the Company’s common stock increasing its beneficial ownership by more than 0.5%. The Rights Agreement and the related Rights expire on November 5, 2020, or earlier upon the occurrence of certain other circumstances specified in the Rights Agreement. The Company intends to submit the Rights Agreement to a vote of its shareholders at the Company’s next annual meeting. For more information, please see the Current Report on Form 8-K filed with the SEC on November 6, 2018.

Accounting Policies (Policies)

Accounting Policies (Policies)	3 Months Ended
	Sep. 30, 2018
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements of Aceto Corporation and subsidiaries (“Aceto” or the “Company”) included herein have been prepared by the Company and reflect all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for all periods presented. Interim results are not necessarily indicative of results which may be achieved for the full year. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (GAAP) requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses reported in those financial statements and the disclosure of contingent assets and liabilities at the date of the financial statements. These judgments can be subjective and complex, and consequently actual results could differ from those estimates and assumptions. The Company’s most critical accounting policies relate to revenue recognition; allowance for doubtful accounts; inventory; goodwill and other indefinite-life intangible assets; long-lived assets; environmental matters and other contingencies; income taxes; stock-based compensation; and purchase price allocation. These condensed consolidated financial statements do not include all disclosures associated with consolidated financial statements prepared in accordance with GAAP. Accordingly, these statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto contained in the Company’s Form 10-K for the year ended June 30, 2018.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement In June 2018, the FASB issued ASU 2018-07 Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. In February 2018, the FASB issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities, In May 2017, the FASB issued ASU 2017-09, Compensation – Stock Compensation (Topic 718): Scope of Modification Accounting, In January 2017, the FASB issued ASU 2017-01 Business Combinations (Topic 805): Clarifying the Definition of a Business In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments, In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) Codification Improvements to Topic 842, Leases Leases (Topic 842), Targeted Improvements

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Sep. 30, 2018
Revenue Recognition [Abstract]
Schedule of revenues disaggregated by business segment and product lines	Three months ended September 30, 2018 Human Health Pharmaceutical Performance Consolidated Finished dosage form generic drugs $ 69,213 - - $ 69,213 Nutraceutical products 11,633 - - 11,633 Pharmaceutical intermediates - $ 10,222 - 10,222 Active pharmaceutical ingredients (APIs) - 28,626 - 28,626 Specialty chemicals - - $ 36,221 36,221 Agricultural protection products - - 8,490 8,490 $ 80,846 $ 38,848 $ 44,711 $ 164,405 Three months ended September 30, 2017 Human Health Pharmaceutical Performance Consolidated Finished dosage form generic drugs $ 95,561 - - $ 95,561 Nutraceutical products 10,454 - - 10,454 Pharmaceutical intermediates - $ 10,136 - 10,136 Active pharmaceutical ingredients (API's) - 26,440 - 26,440 Specialty chemicals - - $ 34,020 34,020 Agricultural protection products - - 8,644 8,644 $ 106,015 $ 36,576 $ 42,664 $ 185,255
Schedule of activity in the consolidated balance sheet for contra assets and liability for price concessions	Accruals for Chargebacks, Rebates, Returns and Other Allowances Government Non-Governmental Sales Chargebacks Returns Reimbursed Rebates Rebates & Other Discounts Balance at June 30, 201 8 $ 66,687 $ 41,511 $ 9,658 $ 86,259 $ 6,408 Current period provision 184,559 6,465 3,061 43,386 6,584 Credits issued during the period (157,732 ) (2,220 ) (3,357 ) (30,717 ) (1,991 ) Balance at September 30, 2018 $ 93,514 $ 45,756 $ 9,362 $ 98,928 $ 11,001

Net Income Per Common Share (Ta

Net Income Per Common Share (Tables)	3 Months Ended
	Sep. 30, 2018
Earnings Per Share [Abstract]
Schedule of reconciliation of weighted average shares outstanding and diluted weighted average shares outstanding	Three Months Ended September 30, 2018 2017 Weighted average shares outstanding 35,487 34,975 Dilutive effect of stock options and restricted stock awards and units - 284 Diluted weighted average shares outstanding 35,487 35,259

Debt (Tables)

Debt (Tables)	3 Months Ended
	Sep. 30, 2018
Debt Disclosure [Abstract]
Schedule of long-term debt	September 30, 2018 June 30, 2018 Convertible Senior Notes, net $ 129,457 $ 127,857 Revolving Bank Loans 62,000 62,000 Term Bank Loans 121,392 124,959 Mortgage 2,533 2,582 315,382 317,398 Less current portion 14,482 14,482 $ 300,900 $ 302,916
Schedule of carrying value of notes	September 30, 2018 June 30, 2018 Principal amount $ 143,750 $ 143,750 Unamortized debt discount (12,518 ) (13,909 ) Unamortized debt issuance costs (1,775 ) (1,984 ) Net carrying value $ 129,457 $ 127,857
Schedule of components of total interest expense related to notes	2018 2017 Contractual coupon $ 670 $ 709 Amortization of debt discount 1,391 1,304 Amortization of debt issuance costs 209 209 $ 2,270 $ 2,222

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of valuation of financial assets and liabilities	Fair Value Measurements at September 30, 2018 Using Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable (Level 3) Total Cash equivalents: Time deposits - $ 3,092 - $ 3,092 Investments: Time deposits - 955 - 955 Foreign currency contracts-assets (1) - 55 - 55 Foreign currency contracts-liabilities (2) - 386 - 386 Derivative asset for interest rate swap (3) - 2,051 - 2,051 Contingent consideration (4) - - $ 703 703 (1) Included in “Other receivables” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (2) Included in “Accrued expenses” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (3) Included in “Other Assets” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. (4) Included in “Long-term liabilities” in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018. Fair Value Measurements at June 30, 2018 Using Quoted Prices Significant (Level 2) Significant Unobservable (Level 3) Total Cash equivalents: Time deposits - $ 3,218 - $ 3,218 Investments: Time deposits - 3,030 - 3,030 Foreign currency contracts-assets (5) - 362 - 362 Foreign currency contracts-liabilities (6) - 304 - 304 Derivative asset for interest rate swap (7) - 1,839 - 1,839 Contingent consideration (8) - - $ 683 683 (5) Included in “Other receivables” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (6) Included in “Accrued expenses” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (7) Included in “Other Assets” in the accompanying Consolidated Balance Sheet as of June 30, 2018. (8) Included in “Long-term liabilities” in the accompanying Consolidated Balance Sheet as of June 30, 2018.

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Sep. 30, 2018
Segment Reporting [Abstract]
Schedule of segment performance measures	Human Pharmaceutical Performance Chemicals Unallocated Consolidated 2018 Net sales $ 80,846 $ 38,848 $ 44,711 $ - $ 164,405 Gross profit 8,476 6,894 10,110 - 25,480 (Loss) income before income taxes (13,047 ) 3,398 5,928 (15,374 ) (19,095 ) 2017 Net sales $ 106,015 $ 36,576 $ 42,664 $ - $ 185,255 Gross profit 24,647 5,840 9,496 - 39,983 Income (loss) before income taxes 5,026 2,231 4,945 (10,064 ) 2,138

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Disaggregation of Revenue [Line Items]
Revenues	$ 164,405	$ 185,255
Finished dosage form generic drugs
Disaggregation of Revenue [Line Items]
Revenues	69,213	95,561
Nutraceutical products
Disaggregation of Revenue [Line Items]
Revenues	11,633	10,454
Pharmaceutical intermediates
Disaggregation of Revenue [Line Items]
Revenues	10,222	10,136
Active pharmaceutical ingredients (APIs)
Disaggregation of Revenue [Line Items]
Revenues	28,626	26,440
Specialty chemicals
Disaggregation of Revenue [Line Items]
Revenues	36,221	34,020
Agricultural protection products
Disaggregation of Revenue [Line Items]
Revenues	8,490	8,644
Human Health
Disaggregation of Revenue [Line Items]
Revenues	80,846	106,015
Human Health | Finished dosage form generic drugs
Disaggregation of Revenue [Line Items]
Revenues	69,213	95,561
Human Health | Nutraceutical products
Disaggregation of Revenue [Line Items]
Revenues	11,633	10,454
Human Health | Pharmaceutical intermediates
Disaggregation of Revenue [Line Items]
Revenues	0	0
Human Health | Active pharmaceutical ingredients (APIs)
Disaggregation of Revenue [Line Items]
Revenues	0	0
Human Health | Specialty chemicals
Disaggregation of Revenue [Line Items]
Revenues	0	0
Human Health | Agricultural protection products
Disaggregation of Revenue [Line Items]
Revenues	0	0
Pharmaceutical Ingredients
Disaggregation of Revenue [Line Items]
Revenues	38,848	36,576
Pharmaceutical Ingredients | Finished dosage form generic drugs
Disaggregation of Revenue [Line Items]
Revenues	0	0
Pharmaceutical Ingredients | Nutraceutical products
Disaggregation of Revenue [Line Items]
Revenues	0	0
Pharmaceutical Ingredients | Pharmaceutical intermediates
Disaggregation of Revenue [Line Items]
Revenues	10,222	10,136
Pharmaceutical Ingredients | Active pharmaceutical ingredients (APIs)
Disaggregation of Revenue [Line Items]
Revenues	28,626	26,440
Pharmaceutical Ingredients | Specialty chemicals
Disaggregation of Revenue [Line Items]
Revenues	0	0
Pharmaceutical Ingredients | Agricultural protection products
Disaggregation of Revenue [Line Items]
Revenues	0	0
Performance Chemicals
Disaggregation of Revenue [Line Items]
Revenues	44,711	42,664
Performance Chemicals | Finished dosage form generic drugs
Disaggregation of Revenue [Line Items]
Revenues	0	0
Performance Chemicals | Nutraceutical products
Disaggregation of Revenue [Line Items]
Revenues	0	0
Performance Chemicals | Pharmaceutical intermediates
Disaggregation of Revenue [Line Items]
Revenues	0	0
Performance Chemicals | Active pharmaceutical ingredients (APIs)
Disaggregation of Revenue [Line Items]
Revenues	0	0
Performance Chemicals | Specialty chemicals
Disaggregation of Revenue [Line Items]
Revenues	36,221	34,020
Performance Chemicals | Agricultural protection products
Disaggregation of Revenue [Line Items]
Revenues	$ 8,490	$ 8,644

Revenue Recognition (Details 1)

Revenue Recognition (Details 1) $ in Thousands	3 Months Ended
	Sep. 30, 2018USD ($)
Chargebacks
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at June 30, 2018	$ 66,687
Current period provision	184,559
Credits issued during the period	(157,732)
Balance at September 30, 2018	93,514
Returns
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at June 30, 2018	41,511
Current period provision	6,465
Credits issued during the period	(2,220)
Balance at September 30, 2018	45,756
Government Reimbursed Rebates
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at June 30, 2018	9,658
Current period provision	3,061
Credits issued during the period	(3,357)
Balance at September 30, 2018	9,362
Non-Governmental Rebates & Other
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at June 30, 2018	86,259
Current period provision	43,386
Credits issued during the period	(30,717)
Balance at September 30, 2018	98,928
Sales Discounts
SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at June 30, 2018	6,408
Current period provision	6,584
Credits issued during the period	(1,991)
Balance at September 30, 2018	$ 11,001

Stock Based Compensation (Narra

Stock Based Compensation (Narrative) (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Dec. 15, 2015	Dec. 06, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (24)	$ 3,146
Unrecognized stock-based compensation cost	$ 4,476
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares	0
Restricted stock | Employees
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares		337
Restricted stock, vesting period		3 years
Performance-vested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock granted, shares		168
Restricted stock, vesting period		3 years
Upper limit of target grant, shares		294
Performance-vested restricted stock units, vesting percentage		100.00%
Restricted common stock and restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ (24)	$ 3,132
Restricted common stock and restricted stock units | Chief executive officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense		$ 2,017
2015 Equity Participation Plan (the "2015 Plan")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued			4,250
2010 Equity Participation Plan (as amended and restated in 2012, the "2010 Plan")
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares of common stock that may be issued				5,250

Capital Stock (Narrative) (Deta

Capital Stock (Narrative) (Detail) - $ / shares shares in Thousands	Sep. 06, 2018	Sep. 30, 2018	Jun. 30, 2018	May 04, 2017
Dividends Payable [Line Items]
Common stock, shares authorized		75,000	75,000
Preferred stock, shares authorized		2,000	2,000
Dividends declared, per share amount	$ 0.01
Dividends declared, date of declaration	Sep. 6, 2018
Dividend paid, date	Oct. 9, 2018
Dividends payable, date to be paid	Oct. 9, 2018
Dividends declared, date of record	Sep. 24, 2018
Stock repurchase program
Dividends Payable [Line Items]
Number of shares authorized to be repurchased				5,000

Net Income Per Common Share (Re

Net Income Per Common Share (Reconciliation of Weighted Average Shares Outstanding and Diluted Weighted Average Shares Outstanding) (Detail) - shares shares in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Earnings Per Share [Abstract]
Weighted average shares outstanding	35,487	34,975
Dilutive effect of stock options and restricted stock awards and units	0	284
Diluted weighted average shares outstanding	35,487	35,259

Net Income Per Common Share (Na

Net Income Per Common Share (Narrative) (Detail) - $ / shares shares in Thousands	1 Months Ended	3 Months Ended
	Dec. 21, 2016	Sep. 30, 2018	Sep. 30, 2017	Nov. 30, 2015
Net Income Per Common Share [Line Items]
Number of shares issued in connection with acquisition included in weighted average shares outstanding		5,122	5,122
Common equivalent shares excluded from computation of earnings per share due to net loss		35	61
Antidilutive securities excluded from computation of earnings per share		1,171
Citron and Lucid
Net Income Per Common Share [Line Items]
Number of shares issued in connection with acquisition included in weighted average shares outstanding	5,122		5,122
Convertible Senior Notes
Net Income Per Common Share [Line Items]
Senior notes, initial conversion price per share				$ 33.215

Debt (Summary of Long-term Debt

Debt (Summary of Long-term Debt) (Detail) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Long-term debt including current portion	$ 315,382	$ 317,398
Less current portion	14,482	14,482
Long-term debt, net	300,900	302,916
Convertible Senior Notes, net
Debt Instrument [Line Items]
Long-term debt including current portion	129,457	127,857
Revolving Bank Loans
Debt Instrument [Line Items]
Long-term debt including current portion	62,000	62,000
Term Bank Loans
Debt Instrument [Line Items]
Long-term debt including current portion	121,392	124,959
Mortgage
Debt Instrument [Line Items]
Long-term debt including current portion	$ 2,533	$ 2,582

Debt (Summary carrying value of

Debt (Summary carrying value of Notes) (Detail 1) - USD ($) $ in Thousands	Sep. 30, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Net carrying value	$ 315,382	$ 317,398
Convertible Senior Notes, net
Debt Instrument [Line Items]
Principal amount	143,750	143,750
Unamortized debt discount	(12,518)	(13,909)
Unamortized debt issuance costs	(1,775)	(1,984)
Net carrying value	$ 129,457	$ 127,857

Debt (Summary interest expense

Debt (Summary interest expense related to notes recognized) (Detail 2) - Interest expense - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Debt Instrument [Line Items]
Contractual coupon	$ 670	$ 709
Amortization of debt discount	1,391	1,304
Amortization of debt issuance costs	209	209
Interest expense	$ 2,270	$ 2,222

Debt (Narrative) (Detail)

Debt (Narrative) (Detail) $ / shares in Units, Share in Thousands, $ in Thousands	1 Months Ended	3 Months Ended
	Nov. 30, 2015USD ($)Share$ / shares	Sep. 30, 2018USD ($)Day
Debt Instrument [Line Items]
Aggregate principal amount of notes	$ 143,750
Convertible Senior Notes due 2020 (the "Notes")
Debt Instrument [Line Items]
Aggregate principal amount of notes	125,000
Aggregate principal amount of additional convertible debt	18,750
Aggregate proceeds from convertible senior notes	$ 143,750
Debt interest rate	2.00%
Number of common stock issue in conversion debt | Share	4,328
Senior notes, initial conversion price per share | $ / shares	$ 33.215
Threshold multiple for debt conversion of notes		$ 1,000
Threshold trading days for convertible debt | Day		20
Threshold consecutive trading days for convertible debt | Day		30
Percentage of minimum stock price trigger for conversion		130.00%
Maximum calculated percentage to which trading price of notes is compared in order to trigger conversion feature of notes		98.00%

Debt (Narrative) (Detail 1)

Debt (Narrative) (Detail 1) $ in Thousands	1 Months Ended	3 Months Ended
	Dec. 21, 2016USD ($)Entity	Sep. 30, 2018USD ($)Installment	Jun. 30, 2018USD ($)	Aug. 26, 2016USD ($)
Debt Instrument [Line Items]
Borrowed loans		$ 315,382	$ 317,398
Second Amended and Restated Credit Agreement (the "A&R Credit Agreement")
Debt Instrument [Line Items]
Number of banks | Entity	11
Revolving Bank Loans
Debt Instrument [Line Items]
Borrowed loans		$ 62,000	62,000
Revolving Bank Loans | Second Amended and Restated Credit Agreement (the "A&R Credit Agreement")
Debt Instrument [Line Items]
Aggregate revolving commitment	$ 225,000			$ 150,000
Maturity date description	Maturity Date shall mean the date that is 91 days prior to the 2015 Convertible Maturity Date
Revolving Bank Loans | Second Amended and Restated Credit Agreement (the "A&R Credit Agreement") | Eurodollar Loan | Minimum
Debt Instrument [Line Items]
Debt interest rate		5.00%
Revolving Bank Loans | Second Amended and Restated Credit Agreement (the "A&R Credit Agreement") | Eurodollar Loan | Maximum
Debt Instrument [Line Items]
Debt interest rate		5.02%
Initial Term Loan
Debt Instrument [Line Items]
Borrowed loans		$ 121,392	$ 124,959
Number of installments | Installment		19
Frequency of periodic payment		Quarterly
Principal payment		$ 3,750
Initial Term Loan | Second Amended and Restated Credit Agreement (the "A&R Credit Agreement")
Debt Instrument [Line Items]
Borrowed loans		150,000
Aggregate amount increase		100,000
Remaining amount outstanding		$ 123,750
Initial Term Loan | Second Amended and Restated Credit Agreement (the "A&R Credit Agreement") | Eurodollar Loan
Debt Instrument [Line Items]
Debt interest rate		9.39%

Debt (Narrative) (Detail 2)

Debt (Narrative) (Detail 2) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 21, 2017	Sep. 30, 2018	Jun. 30, 2018	May 03, 2018
Line of Credit Facility [Line Items]
Borrowed loans		$ 315,382	$ 317,398
Short term loans, fixed interest rate		4.50%
Cash flow hedging | Interest rate swap | December 21, 2021
Line of Credit Facility [Line Items]
Additional interest cost rate of derivative	2.005%
Derivative, notional amount	$ 100,000
Derivative, expiration date	Dec. 21, 2021
Notional balance of derivative		$ 82,500
September 2018 Amendment
Line of Credit Facility [Line Items]
Available revolving commitment		55,000
Remaining amount outstanding		$ 12,300
September 2018 Amendment | Maximum
Line of Credit Facility [Line Items]
Dividend restrictions		$ 325
September 2018 Amendment | ABR Loans
Line of Credit Facility [Line Items]
Debt interest rate		6.00%
September 2018 Amendment | Eurodollar Loan
Line of Credit Facility [Line Items]
Debt interest rate		7.00%
Revolving Bank Loans
Line of Credit Facility [Line Items]
Borrowed loans		$ 62,000	$ 62,000
Revolving Bank Loans | May 2018 Amendment
Line of Credit Facility [Line Items]
Available revolving commitment				$ 100,000

Debt (Narrative) (Detail 3)

Debt (Narrative) (Detail 3) - Mortgage - USD ($) $ in Thousands	1 Months Ended
	Jun. 30, 2011	Sep. 30, 2017
Debt Instrument [Line Items]
Mortgage payable	$ 3,947
Mortgage payable, amortization period	20 years
Debt interest rate		4.92%
Debt Instrument, Maturity Date	Jun. 30, 2021

Commitments, Contingencies an_2

Commitments, Contingencies and Other Matters (Narrative) (Detail) shares in Thousands, $ in Thousands	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 21, 2016USD ($)shares	Sep. 30, 2018USD ($)Entityshares	Sep. 30, 2017USD ($)shares	Jun. 30, 2009USD ($)	Jun. 30, 2018USD ($)
Commitments and Contingencies Disclosure [Line Items]
Environmental charge			$ 902
Number of shares to be issued | shares		5,122	5,122
Contingent consideration		$ 703			$ 683
Citron and Lucid
Commitments and Contingencies Disclosure [Line Items]
Deferred payment	$ 50,000
Interest rate	5.00%
Number of shares to be issued | shares	5,122		5,122
Purchase price, earn-out period	5 years
Purchase price, earn-out amount	$ 50,000
Contingent consideration		703			683
PRP Group
Commitments and Contingencies Disclosure [Line Items]
Loss contingency, damages sought		1,700
Arsynco
Commitments and Contingencies Disclosure [Line Items]
Accrual for environmental loss contingencies		$ 4,943			5,746
Arsynco | Berry's Creek Study Area
Commitments and Contingencies Disclosure [Line Items]
Number of potentially responsible parties | Entity		150
Arsynco | Agreement to sell the Arsynco property | Environmental Remediation property for sale
Commitments and Contingencies Disclosure [Line Items]
Expected sale of property value					6,340
Arsynco | Minimum
Commitments and Contingencies Disclosure [Line Items]
Estimated cost of environmental remediation obligations		$ 22,900
Arsynco | Maximum
Commitments and Contingencies Disclosure [Line Items]
Estimated cost of environmental remediation obligations		24,700
BASF
Commitments and Contingencies Disclosure [Line Items]
Partial reimbursement of environmental remediation costs previously expensed				$ 550
Gain related to partial reimbursement				550
Environmental remediation costs expensed in prior years				$ 1,200
Future remediation costs receivable		2,224			$ 2,586
Subsidiary
Commitments and Contingencies Disclosure [Line Items]
Amount expected to be paid for product registrations and various task force groups		$ 5,616

Fair Value Measurements (Summar

Fair Value Measurements (Summary of Valuation of Financial Assets and Liabilities) (Detail 1) - USD ($) $ in Thousands	Sep. 30, 2018		Jun. 30, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	$ 55	[1]	$ 362	[2]
Foreign currency contracts-liabilities	386	[3]	304	[4]
Derivative asset for interest rate swap	2,051	[5]	1,839	[6]
Contingent consideration	703	[7]	683	[8]
Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,092		3,218
Investments	955		3,030
Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	0	[1]	0	[2]
Foreign currency contracts-liabilities	0	[3]	0	[4]
Derivative asset for interest rate swap	0	[5]	0	[6]
Contingent consideration	0	[7]	0	[8]
Quoted Prices in Active Markets (Level 1) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Investments	0		0
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	55	[1]	362	[2]
Foreign currency contracts-liabilities	386	[3]	304	[4]
Derivative asset for interest rate swap	2,051	[5]	1,839	[6]
Contingent consideration	0	[7]	0	[8]
Significant Other Observable Inputs (Level 2) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	3,092		3,218
Investments	955		3,030
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts-assets	0	[1]	0	[2]
Foreign currency contracts-liabilities	0	[3]	0	[4]
Derivative asset for interest rate swap	0	[5]	0	[6]
Contingent consideration	703	[7]	683	[8]
Significant Unobservable Inputs (Level 3) | Time deposits
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0		0
Investments	$ 0		$ 0
[1]	Included in "Other receivables" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018.
[2]	Included in "Other receivables" in the accompanying Consolidated Balance Sheet as of June 30, 2018.
[3]	Included in "Accrued expenses" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018.
[4]	Included in "Accrued expenses" in the accompanying Consolidated Balance Sheet as of June 30, 2018.
[5]	Included in "Other Assets" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018.
[6]	Included in "Other Assets" in the accompanying Consolidated Balance Sheet as of June 30, 2018.
[7]	Included in "Long-term liabilities" in the accompanying Condensed Consolidated Balance Sheet as of September 30, 2018.
[8]	Included in "Long-term liabilities" in the accompanying Consolidated Balance Sheet as of June 30, 2018.

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Detail) - USD ($) shares in Thousands, $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 21, 2017	Dec. 21, 2016	Sep. 30, 2018	Sep. 30, 2017	Jun. 30, 2018	Nov. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized gain on interest rate swap			$ 2,051
Accrued contingent consideration			$ 703		$ 683
Number of shares to be issued			5,122	5,122
Aggregate principal amount of notes						$ 143,750
Theoretical borrowing rate used to calculate fair value of debt						6.50%
Fair value of the notes			$ 109,000
Fair value of future issuance of shares			90,400
Human Health Segment - Rising Reporting Unit
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Recognized non-cash goodwill impairment charge, before tax					235,110
Foreign currency contract
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative, notional amount			67,797
Unrealized gains (losses) on hedging activities			(331)	$ 295
Cash flow hedging | December 21, 2021 | Interest rate swap
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Additional interest cost rate of derivative	2.005%
Derivative, notional amount	$ 100,000
Derivative, expiration date	Dec. 21, 2021
Notional balance of derivative			82,500
Citron and Lucid
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Accrued contingent consideration			$ 703		$ 683
Number of shares to be issued		5,122		5,122

Segment Information (Summary of

Segment Information (Summary of Segment Perfomance Measures by Segment) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Segment Reporting Information [Line Items]
Net sales	$ 164,405	$ 185,255
Gross profit	25,480	39,983
(Loss) income before income taxes	(19,095)	2,138
Human Health
Segment Reporting Information [Line Items]
Net sales	80,846	106,015
Pharmaceutical Ingredients
Segment Reporting Information [Line Items]
Net sales	38,848	36,576
Performance Chemicals
Segment Reporting Information [Line Items]
Net sales	44,711	42,664
Operating Segments | Human Health
Segment Reporting Information [Line Items]
Net sales	80,846	106,015
Gross profit	8,476	24,647
(Loss) income before income taxes	(13,047)	5,026
Operating Segments | Pharmaceutical Ingredients
Segment Reporting Information [Line Items]
Net sales	38,848	36,576
Gross profit	6,894	5,840
(Loss) income before income taxes	3,398	2,231
Operating Segments | Performance Chemicals
Segment Reporting Information [Line Items]
Net sales	44,711	42,664
Gross profit	10,110	9,496
(Loss) income before income taxes	5,928	4,945
Unallocated Corporate
Segment Reporting Information [Line Items]
Net sales	0	0
Gross profit	0	0
(Loss) income before income taxes	$ (15,374)	$ (10,064)

Segment Information (Narrative)

Segment Information (Narrative) (Detail)	3 Months Ended
	Sep. 30, 2018Segment
Segment Reporting [Abstract]
Number of operating segments	3

Subsequent Event (Detail Textua

Subsequent Event (Detail Textuals) - Subsequent event - Rights Agreement	Nov. 05, 2018$ / sharesshares
Subsequent Event [Line Items]
Number of preferred stock authorized and declared as dividends | shares	1
Description of the number of preferred stock issued as dividend for each right issued	one one-thousandth
Series A Participating Cumulative Preferred Stock
Subsequent Event [Line Items]
Par value of preferred stock (in dollars per share)	$ 2.50
purchase price of the one one-thousandth of a share of preferred stock (in dollars per share)	$ 10.85
Minimum percentage of beneficial ownership acquired	4.99%
Minimum percentage increase in common stock beneficial ownership	0.50%